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Introduction: The ﬁve-year survival rate of patients with Non-Small 
Cell Lung Cancer (NSCLC) after surgical resection ranges from 28% 
(Stage IIB) to 62% (Stage IA). Although gene expression signatures 
can be used to predict overall survival in NSCLC patients, there is 
still a need for novel biomarkers that can identify patients who have 
the highest likelihood of recurrence and thus might beneﬁt most from 
adjuvant treatment. Since it has recently been shown that chemotherapy 
in combination with anti-angiogenesis therapy can prolong survival in 
patients with NSCLC, we evaluated the prognostic value of angiogen-
esis gene expression signatures for survival in early stage NSCLC.
Methods: 115 consecutive patients with early stage NSCLC were in-
cluded based on at least 50% tumour area in the fresh frozen resection 
specimen and the absence of other malignancies. No patient received 
postoperative chemotherapy or neo-adjuvant treatment. A training set 
of 58 patients was selected and divided into short survival (<2 years, 
n=31) and long survival (>4 years, n=27). Microvessel density (MVD; 
number of vessels/mm3) was assessed in ﬁve randomly selected high 
power ﬁelds following immunohistochemistry. The angiogenesis gene 
expression signature was determined using real-time PCR covering 24 
genes involved in angiogenesis. 
Results: There was no signiﬁcant difference in MVD between patients 
with short or long survival (3.27±1.34 vs. 2.92±1.03, respectively, 
p=0.293). In addition, there was no correlation between MVD and 
overall survival (corr. coef. -0.102, p=0.457). For real-time PCR, ﬁve 
reference genes were selected, i.e. β-Actin, cyclophilin-A, GAPDH, 
HPRT-1 and β-2-Microglobulin. Using correlation analysis and Ge-
Norm analysis, we identiﬁed HPRT-1, GAPDH, and β-2-microglobu-
line as the most stable reference genes. Following angiogenesis gene 
expression proﬁling and subsequent univariate analysis, we observed 
a signiﬁcant increase in the expression levels of VEGF-C (2.5 fold, 
p=0.008), Angiopoietin-1 (2.5 fold, p=0.024), and Neuropilin-1 (2.35 
fold, p=0.010) in patients with a short survival compared to those with 
a long survival. Expression levels of VEGF-A/-B/-D, VEGF-R1/-
R2/-R3, Angiopoietin-2, Neuropilin-2, Tie-1/-2, PDGF-B, PlGF, EGF, 
ICAM-1, VCAM, bFGF, TNFα, TGFα/β, IL-8, Trombospondin-1 were 
not signiﬁcantly altered. Based on all expression data, we developed 
a preliminary model that predicts the probability of 2-years overall 
survival of early stage NSCLC patients. Cross validation and boot-
strapping revealed a sensitivity of 60% and a speciﬁcity of 70% of this 
preliminary model. 
Conclusion: Microvessel density was not a prognostic factor for 
survival in early stage NSCLC patients. Nevertheless, we found altered 
expression levels of angiogenesis factors in patients with short survival. 
Furthermore, we developed a model that predicts the 2-years over-
all survival of early stage NSCLC patients. Current research aims at 
increasing the sensitivity and speciﬁcity of the model by extending the 
training set and by model validation of an independent set of samples, 
these data will be presented.
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Background: Insulin-like growth factor pathway is implicated in 
malignant transformation and growth of several tumor types, includ-
ing NSCLC. In the present study, we investigated the prognostic 
signiﬁcance of IGF1R expression in operable NSCLC patients. Several 
inhibitors of IGF1R are currently in development and this study aimed 
to evaluate the NSCLC patient subset who may beneﬁt from these 
therapies.
Methods: This study was performed on a tissue microarray (TMA) 
constructed from samples from 191 surgically treated NSCLC patients. 
The tissue 1.5 µm diameter cores were obtained in triplicates using 
commercially available MaxArray kit from Invitrogen (Carlsbad, CA, 
USA). Study group included 23% females, 55% patients with squa-
mous cell carcinoma, 28% with adenocarcinoma, 3% with large cell 
carcinoma, 14% with mixed carcinoma/other histologies. There were 
5% never-smokers and median age was 64 years (range: 37-85 years). 
Pathological stage I was diagnosed in 41%, stage II - 22%, stage III 
- 33% and stage IV - 4% pts. 
Staining was performed with Novus mouse anti-human monoclonal 
IGF1R antibody with 1:25 dilution for 60 min. after pressure-cooker 
antigen retrieval in TRS with pH=6.0. Scoring was done using H-score, 
taking into account proportion of cells with positive staining and stain-
ing intensity graded from 0 to 4. Total H-score ranged from 0 to 400.
Results: IGF1R IHC expression was evaluated by two observers with 
high concordance (r2=0.76), 9% of samples required consensus read-
ing. Median H-score was 20 (range: 0-223). Higher IGF1R score was 
observed in adenocarcinomas vs. squamous-cell carcinomas (p=0.02) 
and never-smokers vs. smokers (p=0.02). There was no difference in 
IGF1R expression according to stage (p=0.98) and sex (p=0.83). In the 
univariate Cox regression analysis, IGF1R analyzed as a continuous 
variable tended to associate with worse survival in the entire cohort 
(p=0.10), and was signiﬁcantly associated with inferior survival in 
patients with complete (R0) resections (p=0.04). Using cut-off point 
H-score of 50 (30% of patients positive), IGF1R expression was again 
associated with poor survival (p=0.05). This association was restricted 
to pathological stage I (hazard ratio, HR=3.07; 95% conﬁdence 
interval, CI=1.41-6.70, p=0.005) vs. all other stages (HR=1.03; 95% 
CI=0.63-1.70, p=0.90), and to patients with adenocarcinoma (HR=2.67; 
95%CI=1.17-6.70, p=0.02 vs. all other histologies (HR=1.28; 
95%CI=0.79-2.11, p=0.32).
Conclusion: High IGF1R expression is associated with adenocarci-
noma histology, never-smoking history and indicates poor prognosis, 
particularly in patients with stage I NSCLC and adenocarcinomas. 
